# PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC

Source: https://onco.cc/trials/nct07416058/  
OnCo record `nct07416058` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of iparomlimab and tuvonralimab in lung cancer, run by Guangdong Association of Clinical Trials, not yet recruiting.

## Summary

PHOENIX: QL1706 Plus Chemotherapy and Bevacizumab in AGA-Resistant, PD-L1 ≥50% Non-Squamous NSCLC is a phase 2, interventional study registered as NCT07416058 by Guangdong Association of Clinical Trials, with a registry enrolment figure of 61 participants, started 2026-01-31 and due to reach its primary completion in 2027-12-31. Interventions recorded: QL1706 (bispecific antibody targeting PD-1 and CLTA-4). Conditions listed: Lung Adenocarcinoma. Primary outcome: Objective Response Rate (ORR) per RECIST 1.1. Lung eligibility wording from the registry: "The study will enroll adult patients (aged 18-75 years) with histologically confirmed locally advanced or metastatic NSCLC (AJCC 9th Edition, Stage IIIB-IVB), and harbor confirmed actionable driver mutations for which targeted therapies are available; these mutations are stratified as follows: EGFR ". No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-25
- Also known as: PHOENIX
- Tags: ctgov-ingest; lung-deep-dive
- Registry id: NCT07416058
- Phase: 2
- Setting: A Multicenter Study of Iparomlimab and Tuvonralimab (QL1706) Plus Platinum-Based Doublet Chemotherapy and Bevacizumab in PD-L1 ≥50% Non-Squamous Non-Small Cell Lung Cancer With Actionable Genomic Alterations (AGA) Resistant to Prior Targeted Therapy
- Sponsor: Guangdong Association of Clinical Trials
- Enrolled: 61

## Sources

- ClinicalTrials.gov NCT07416058: https://clinicaltrials.gov/study/NCT07416058

## Connected records

- cancers: [Adenocarcinoma of the lung](https://onco.cc/cancers/lung-adenocarcinoma/)
- drugs: [Iparomlimab and tuvonralimab](https://onco.cc/drugs/iparomlimab-tuvonralimab/)
- companies: [Qilu Pharmaceutical](https://onco.cc/companies/qilu-pharmaceutical/)
- terms: [Lung cancer trials open today (registry snapshot)](https://onco.cc/terms/lung-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07416058.json